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Reversible MAO-A inhibitorMonoamine oxidase (MAO) inhibitors were the ﬁrst antidepressant drugs to be prescribed and are still used
today with great success, especially in patients resistant to other antidepressants. In this study, we evaluated the
MAO inhibitory properties and the potential antidepressant action of 2-(3,4-dimethoxy-phenyl)-4,5-dihydro-
1H-imidazole (2-DMPI) in mice. We found that 2-DMPI inhibited both MAO isoforms (Ki values were 1.53 (1.3–
1.8) μM and 46.67 (31.8–68.4) μM for MAO-A and MAO-B, respectively) with 30-fold higher selectivity toward
MAO-A. In relation to the nature ofMAO-A inhibition, 2-DMPI showed to be amixed and reversible inhibitor. The
treatment with 2-DMPI (100–1000 μmol/kg, s.c.) caused a signiﬁcant decrease in immobility time in the tail
suspension test (TST) without affecting locomotor activity, motor coordination or anxiety-related activities.
Conversely, moclobemide (1000 μmol/kg, s.c.) caused a signiﬁcant increase in immobility time in the TST, which
appeared to be mediated by a nonspeciﬁc effect on motor coordination function. 2-DMPI (300 μmol/kg, s.c.)
decreased serotonin turnover in the cerebral cortex, hippocampus and striatum, whereas dopamine turnover
was diminished only in the striatum, and norepinephrine turnover was not changed. The antidepressant-like
effect of 2-DMPI was inhibited by the pretreatment of mice with methysergide (2 mg/kg, s.c., a non-selective
serotonin receptor antagonist), WAY100635 (0.1 mg/kg, s.c., a selective 5-HT1A receptor antagonist) or
haloperidol (0.05 mg/kg, i.p., a non-selective dopamine receptor antagonist). These results suggest that
2-DMPI is a prototype reversible and preferential MAO-A inhibitor with potential antidepressant activity, due to
its modulatory effect on serotonergic and dopaminergic systems.
© 2012 Elsevier Inc.Open access under the Elsevier OA license. 1. Introduction
Depression is a chronic, recurring and potentially life-threatening
psychiatric illness that affects approximately 20% of the worldwide
population (Berton and Nestler, 2006). Although several different
antidepressant drugs are available to treat depression, all of these
compounds modulate monoamine neurotransmission, specially sero-
tonergic and noradrenergic systems (Wong and Licinio, 2004).
However, increasing evidence from human and animal studies
suggest a relationship between dopamine (DA) neurotransmission
and depression (Dailly et al., 2004; Millan, 2004; Papakostas, 2006).
Monoamine oxidase (MAO; EC 1.4.3.4) catalyses the oxidative
deamination of biogenic amines, such as serotonin (5-hydroxytryp-
tamine, 5-HT), norepinephrine (NE) and DA, and it seems to play: +55 55 3220 8756.
vier OA license. important roles in several psychiatric and neurological disorders.
MAO is aﬂavin adenine dinucleotide (FAD)-dependent enzyme located at
the outer mitochondrial membrane of monoaminergic neurons, glia, and
other cells. On the basis of pharmacological, biochemical and genetic
studies, two isoforms of MAO were proposed and designated MAO-A
and MAO-B (Bach et al., 1988; Johnston, 1968). MAO-A preferentially
deaminates 5-HT and is inhibited by low concentrations of clorgyline,
whereas MAO-B deaminates phenylethylamine and benzylamine
and is inhibited by low concentrations of selegiline. Epinephrine, NE,
DA, tryptamine and tyramine are oxidized by both isoforms of the
enzyme in most species (Youdim et al., 2006).
Monoamine oxidase inhibitors (MAOIs) have been used for decades
in the treatment of depression and their antidepressant properties
result from selective MAO-A inhibition in the central nervous system,
which could lead to increased brain levels of 5-HT, NE and DA (López-
Muñoz et al., 2007; Robinson, 2002). Moreover, Meyer et al. (2006),
using positron emission tomography, found a marked increase in brain
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with healthy subjects, suggesting that elevated MAO-A levels may be
the primary cause ofmonoamine depletion in depression. In fact,MAOIs
were the ﬁrst antidepressant drugs described and are still used today
with great success, especially in patients who are resistant to other
treatments (Berton and Nestler, 2006; López-Muñoz et al., 2007; Thase
et al., 1995; Wong and Licinio, 2004). Although the ﬁrst generation
of irreversible and nonselective MAOIs (i.e., phenelzine and tranylcy-
promine) displayed antidepressant activity, they induced serious side
effects, such as acute hypertensive crises, when given in combination
with foods containing tyramine. These liabilities led to the search for
a second generation of MAOIs (i.e., clorgyline) that exhibited an
irreversible and selective proﬁle. However, undesirable hypertensive
crises persisted, limiting the use of second-generation MAOIs. After-
ward, selective and reversible MAO-A inhibitors, having a much better
safety proﬁle than irreversible inhibitors, have been described (López-
Muñoz et al., 2007; Robinson, 2002).
Recently, a series of 2-substituted-2-imidazoline compounds were
synthesizedusing a greener synthetic approach, and their ability to inhibit
in vitro MAO activity was evaluated in rat brain (Sant'Anna et al., 2009).
Potent and selective inhibitory activities toward both MAO isoforms
were observed for certain compounds, including 2-(3,4-dimethoxy-
phenyl)-4,5-dihydro-1H-imidazole (2-DMPI). Thus, the aims of this
study were to evaluate the MAO inhibitory properties of 2-DMPI in
mice brain and its effects on a predictive test for antidepressant
activity (the tail suspension test), as well as on monoamine
metabolism and the participation of the monoaminergic system in the
potential antidepressant-like action of this compound. We also
investigated the effect of 2-DMPI during tests of locomotor activity,
motor coordination and anxiety-related activities.
2. Materials and methods
2.1. Animals
Male Swiss mice (25–30 g) from our own colony were used in this
study. Mice were maintained in polycarbonate cages with free access
to food and water and on a 12 h alternating light–dark schedule in a
temperature-controlled room (22±3 °C). The animals were allowed
to adapt to the test environment for 2 days before testing. Mice were
kept and used in accordance to the guidelines of the National Council
for Control of Animal Experiments (CONCEA) and the National
Institutes of Health guide for the care and use of Laboratory Animals.
All experiments pertaining to this study were approved by the Ethics
Committee of the Federal University of Santa Maria (process number
59/2008). For behavioral tests, drugs were administered in random
order, and the behavioral measure was carried out by a blinded
investigator. Each mouse was tested individually and only once.
Results of mice treated with any drug were compared with those
obtained for a vehicle treated (control) group.
2.2. Drugs
The synthesis of 2-DMPI was carried out by the previously
reported method of condensation involving aldehydes and ethylene-
diamine in the presence of N-bromosuccinimide (Sant'Anna et al.,
2009). The chemical structure of 2-DMPI is shown in Fig. 1A. Analysis
of 1H and 13C Nuclear magnetic resonance spectra showed analytical
and spectroscopic data in full agreement with the assigned structure.
For in vivo studies, 2-DMPI and moclobemide (Aurorix®, Roche, Brazil)
were dissolved in a vehicle solution (5% Tween 80, 20% polyethylene-
glycol and 75% saline), and for in vitro studies, in 10% dimethyl sulfoxide
(maximum ﬁnal concentration of 1%). WAY100635 and methysergide
(Sigma Chemical Co., St. Louis, USA), diazepam (Compaz®, Cristália,
Brazil) and haloperidol (Haldol®, Janssen-Cilag, Brazil) were dissolved
in saline. All other reagentswere of analytical grade andwere purchasedfrom local suppliers. Injections were performed in a 10 mL/kg volume
by the subcutaneous (s.c.) or intraperitoneal (i.p.) route.
2.3. Biochemical measurements
2.3.1. Determination of the kinetic parameters of MAO inhibition in vitro
2-DMPI was tested for its in vitro inhibitory potential on mice
MAO-A and MAO-B activities in brain mitochondrial preparations by
a ﬂuorometric method using kynuramine as a substrate, as previously
described (Matsumoto et al., 1985; Sant'Anna et al., 2009). Brieﬂy,
assays were performed in duplicate in a ﬁnal volume of 500 μL
containing 0.45 mg of protein and incubated at 37 °C for 30 min.
Activities of the A and B isoforms were isolated pharmacologically
by incorporating 250 nM selegiline (selective MAO-B inhibitor) or
250 nM clorgyline (selective MAO-A inhibitor) into the reaction mix.
The reaction mixture (containing mitochondrial fractions, 2-DMPI
and inhibitors) was preincubated at 37 °C for 5 min, and the reaction
was started by the addition of 50 μL of kynuramine (90 μM for MAO-A
and 60 μM for MAO-B). Also, 2-DMPI andmoclobemide were tested at
a concentration range of 1 to 1000 μM, and the IC50 and Ki values for
both MAO isoforms were determined.
For kinetic experiments, various concentrations of kynuramine
(1–300 μM) were used, and the MAO-A activity was determined in
the absence or presence of different concentrations of 2-DMPI (10, 30
or 100 μM) in order to calculate Km and Vmax values.
The reversibility of MAO-A inhibition was studied using the
dialysis method as described by Harfenist et al. (1996) with minor
modiﬁcations. Mixtures of buffer, brain mitochondrial preparations
and selegiline with and without 2-DMPI (30 μM) were dialyzed at
25 °C for 24 h. In the control mixture, 0.003% dimethyl sulfoxide
(DMSO) was added. For each 1 mL of mixture dialyzed, 40 mL of
outer buffer (16.8 mM Na2HPO4, 10.6 mM KH2PO4, 3.6 mM KCl, 1 mM
dithiothreitol) was used. The outer buffer was replaced with fresh
buffer at 1, 2, 4 and 6 h after the start of dialysis. Undialyzed portions
of each mixture were maintained at 25 °C over the same time period.
Twenty-four hours after the start of dialysis, dialyzed and undialyzed
mixtures were simultaneously assayed for MAO-A activity in order to
evaluate the reversibility of the inhibition produced by 2-DMPI.
2.3.2. Monoamine neurotransmitters and metabolites levels
Micewere killed 2 h after the administration of 2-DMPI (300 μmol/kg,
s.c.) or vehicle solution (10 mL/kg, s.c.). The brains were excised, and
the cerebral cortex, hippocampus and striatum were immediately
separated and stored at −80 °C until analyzed by high-performance
liquid chromatography (HPLC). The levels of themonoamines DA, 5-HT,
NE and their metabolites homovanillic acid (HVA), 3,4-dihydroxyphe-
nylacetic acid (DOPAC), 5-hydroxyindole acetic acid (5-HIAA) and
3,4-dihydroxyphenylglycol (DHPG) were estimated by high perfor-
mance liquid chromatography (HPLC) with electrochemical detection,
as described by Ferraz et al. (2002).
2.4. Behavioral measurements
2.4.1. Tail suspension test (TST)
Antidepressant-like effect was measured using the tail suspension
test (Steru et al., 1985), with minor alterations (Tonello et al., 2012).
Mice were suspended by their tail using adhesive tape placed
approximately 1 cm from the tip of the tail and hung approximately
30 cm above the table. The animals were suspended for a period of
6 min, and the duration of immobility was scored manually during
the last 4 min interval of the test (activity in the ﬁrst 2 min was
discarded because animals predominantly try to escape during this
period). Mice were considered immobile only when they hung
passively.
For the time–course curve, mice were submitted to the TST 0.5, 1,
2, 4 or 6 h after the administration of 2-DMPI (300 μmol/kg, s.c.) or
Fig. 1. (A) Molecular structure of 2-DMPI. (B) Inhibitory potential of 2-DMPI on in vitro MAO-A and MAO-B activities in the mitochondrial fraction of mouse brain. (C) Substrate
concentration curves for in vitro MAO-A activity in the absence or presence of 2-DMPI (10, 30 or 100 μM) in the mitochondrial fraction of mouse brain. (D) Reversibility of MAO-A
inhibition produced by 2-DMPI (30 μM) after 24 h of dialysis. Values are means±SEM of three to four experiments performed in duplicate. ***Pb0.001 compared with the
respective control group, two-way ANOVA followed by Bonferroni's test.
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were treated with 2-DMPI (30, 100, 300 or 1000 μmol/kg, s.c.;
equivalent to 6, 21, 62 or 206 mg/kg, respectively) or vehicle solution
2 h before the TST. Moclobemide (30, 100, 300 or 1000 μmol/kg, s.c.,
1 h before testing; equivalent to 8, 27, 81 or 269 mg/kg, respectively)
was used as a positive control.
To assess the involvement of serotonergic and dopaminergic
systems in the antidepressant-like effect of 2-DMPI, mice received a
single injection of methysergide (2 mg/kg, s.c., a non-selective 5-HT
receptor antagonist), WAY100635 (0.1 mg/kg, s.c., a selective 5-HT1A
receptor antagonist), haloperidol (0.05 mg/kg, i.p., a non-selective DA
receptor antagonist) or saline (10 mL/kg) 30 min before the admin-
istration of 2-DMPI (300 μmol/kg, s.c.) or vehicle. Two hours after
treatment with 2-DMPI or vehicle, the animals were submitted to the
TST. All doses of antagonists used in this work were chosen according
previously published data (Duarte et al., 2008; Machado et al., 2007).
2.4.2. Open ﬁeld test
Spontaneous locomotor activity was assessed in an open ﬁeld test,
as described previously (Archer, 1973). Animals were injected with
2-DMPI (300 μmol/kg, s.c.) or vehicle 2 h before testing. Another
group of mice was treated with moclobemide (300 μmol/kg, s.c.) or
vehicle 1 h before testing. The number of crossings and rearings were
counted in a 5 min session.
2.4.3. Rota-rod test
Motor coordination activity was evaluated using the rota-rod test
(Dunham and Miya, 1957) with minor alterations (Godoy et al.,
2004). The apparatus consisted of a bar (3.7 cm in diameter) divided
into 3 separate compartments, placed at a 25 cm height and rotating
at a ﬁxed velocity of 8 rpm. Twenty-four hours before testing, all
animals were submitted to a training session until they could remain
in the apparatus for 60 s without falling. On the test day, mice
received a single injection of 2-DMPI (300 or 1000 μmol/kg, s.c.) orvehicle 2 h before testing. Another group of mice was treated with
moclobemide (300 or 1000 μmol/kg, s.c.) or vehicle 1 h before testing.
During the test session, the total number of falls during a 4 min period
was observed.
2.4.4. Elevated plus-maze test
Anxiety-related behavior was assessed using the mouse elevated
plus-maze test (Lister, 1987). The apparatus consists of two open
arms (30×5 cm) and two enclosed arms (30×5×15 cm) positioned
40 cm above the ﬂoor. The junction of the four arms forms a central
square platform (5×5 cm). Mice received a single administration of
2-DMPI (300 μmol/kg, s.c.) or vehicle 2 h before testing. As a positive
control, diazepam (1 mg/kg, s.c.) was administered to mice 30 min
before testing (Naderi et al., 2008). Each animal was placed in the
central platform facing one of the open arms and was allowed to
explore freely for 5 min. The behavior parameters recorded were the
number of entries into the open or closed arms and the average time
spent by the mouse in each of the arms. The percentage of the time
spent on the open arms and the percentage of the entries into the
open arms were calculated as follows: time spent or number of
entries into the open arms/total time or total number of the entries
into closed and open arms ×100, respectively.
2.5. Statistical analysis
Data were analyzed using GraphPad Prism 4.0 software. The
results were expressed as means±SEM, except for Ki values, which
were reported as means followed by 95% conﬁdence intervals. Also,
the number of crossings or rearings (open ﬁeld test) and fall number
(rota-rod test) were expressed as medians followed by their 25th and
75th percentiles. IC50 values were calculated by nonlinear regression
using sigmoidal dose–response with a variable slope equation,
whereas Km (μM) and Vmax (nmol/min/mg protein) values were
calculated by nonlinear regression using the Michaelis–Menten
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equation: Ki=IC50/[1+([S]/Km)] (Cheng and Prusoff, 1973). Differences
between groups were evaluated for signiﬁcance using the unpaired
t-test, one-way analysis of variance (ANOVA) followed by Student–
Newman–Keuls test or two-way ANOVA followed by Bonferroni's test
for parametric data. The Mann–Whitney test was used to analyze
nonparametric data (number of crossings, number of rearings and fall
number). Signiﬁcance was considered to be when Pb0.05.Fig. 2. (A) Inhibitory potential of moclobemide on in vitroMAO-A and MAO-B activities
in the mitochondrial fraction of mouse brain. Values are means±SEM of three
experiments performed in duplicate. (B) Effect of moclobemide administration
(30–1000 μmol/kg, s.c.) on immobility time in the TST in mice. Values are means±
SEM for each group (n=5–9 per group). *Pb0.05 and **Pb0.01 compared with the3. Results
3.1. Effects of 2-DMPI on MAO activity
We observed that 2-DMPI inhibited both MAO isoforms in a
concentration-dependent manner with Ki values of 1.5 (1.3–1.8) μM
and 46.7 (31.8–68.4) μM and nH values of 0.91±0.05 and 0.93±0.15
for MAO-A and MAO-B, respectively (Fig. 1B). Subsequently, kinetic
experiments for MAO-A activity were carried out using different
concentrations of substrate. 2-DMPI (30 μM) caused an increase
in the Km value (50.2±10.0 μM) and a decrease in the Vmax value
(0.29±0.02 nmol/min/mg protein) compared to Km and Vmax values
obtained in the absence of 2-DMPI (13.6±2.1 μM and 0.53±
0.02 nmol/min/mg protein, respectively) (Fig. 1C). We evaluated the
reversibility of the MAO-A inhibition induced by 2-DMPI using the
dialysis method. It was observed that the inhibition of MAO-A
activity produced by 2-DMPI was completely reversed after 24 h of
dialysis compared with undialyzed activity (Fig. 1D). We also
determined the inhibitory effect of moclobemide on MAO-A and
MAO-B activities. Moclobemide selectively inhibited the MAO-A
isoform in a concentration-dependent manner, showing a Ki value of
7.4 (6.3–8.7) μM and an nH value of 0.72±0.05 (Fig. 2A).vehicle-treated group, one-way ANOVA followed by the Student–Newman–Keuls test.3.2. Effects of 2-DMPI in the TST
Moclobemide, used as a positive control, signiﬁcantly decreased the
immobility time at doses 100 (35±8%) and 300 (40±7%) μmol/kg
when administered 1 h before testing (F(4, 33)=12.32, Pb0.0001).
However, at 1000 μmol/kg, moclobemide caused a signiﬁcant increase
(27±13%) in immobility time compared to the vehicle-treated group
(Fig. 2B). Systemic treatment with 2-DMPI (300 μmol/kg, s.c.) signiﬁ-
cantly reduced the immobility time at 2 h and 4 h after administration
(F(1,73)=10.07, Pb0.01). This effectwas not found at 0.5, 1 or 6 h after
treatment (data not shown). Therefore, a 2 h pretreatment was chosen
to carry out the dose–response curve and the following experiments. A
signiﬁcant reduction in immobility timewas observed at 100 (34±7%),
300 (46±6%) and 1000 (29±6%) μmol/kg doses of 2-DMPI (F(4,50)=
8.41, Pb0.0001; Fig. 3).Fig. 3. Dose–response curve of subcutaneous (s.c.) 2-DMPI administration on
immobility time in the TST in mice. The values are means±SEM for each group
(n=10–14 per group). **Pb0.01 and ***Pb0.001 compared with the control group,
one-way ANOVA followed by the Student–Newman–Keuls test.3.3. Effects of 2-DMPI in the open ﬁeld and the rota-rod tests
The treatment with 2-DMPI (300 μmol/kg, s.c., 2 h before testing)
did not cause signiﬁcant alterations in both crossing (Fig. 4A) and
rearing (Fig. 4B) numbers compared with vehicle-treated mice.
Moclobemide (300 μmol/kg, s.c., 1 h before testing) caused no
change in the number of crossings (Fig. 4C); however, it signiﬁcantly
decreased the rearing number compared with control mice (Fig. 4D).
In addition, 2-DMPI (300 or 1000 μmol/kg, s.c., 2 h before testing;
Fig. 5A or B, respectively) caused no change in motor coordination
activity compared with control animals, as evaluated by the total
fall number in the rota-rod test. On the other hand, moclobemide
(1000 μmol/kg, s.c., 1 h before testing) caused a signiﬁcant increase
in the total fall number compared to vehicle-treated mice (Fig. 5D).
At a dose of 300 μmol/kg, moclobemide did not alter the motor
coordination function of mice (Fig. 5C).3.4. Effects of 2-DMPI in the plus-maze test
As shown in Fig. 6, 2-DMPI (300 μmol/kg, s.c., 2 h before testing) did
not cause any changes in the percentage of time (Fig. 6A) or percentage
of entries (Fig. 6B) into the open arms compared to vehicle-treated
mice. Diazepam (1 mg/kg, s.c.), used as positive control in this test,
signiﬁcantly increased the percentage of time (F(2,24)=4.31, Pb0.05;
Fig. 6A) and percentage of entries (F(2,24)=8.54, Pb0.01; Fig. 6B) in
the open arms compared to vehicle-treated mice.
3.5. Effects of 2-DMPI on monoamine neurotransmitter levels and its
metabolites
We observed that 2-DMPI (300 μmol/kg, s.c.) induced a signiﬁcant
increase in hippocampal (Fig. 7A), cortical (Fig. 7B) and striatal
Fig. 4. Effects of 2-DMPI (300 μmol/kg, s.c., 2 h before test), moclobemide (300 μmol/
kg, s.c., 1 h before test) or vehicle (10 mL/kg, s.c., 1 or 2 h before test) treatment on
locomotor activity in the open ﬁeld test in mice. (A) Effect of 2-DMPI on crossing
number. (B) Effect of 2-DMPI on rearing number. (C) Effect of moclobemide on
crossing number. (D) Effect of moclobemide on rearing number. Values are medians
(interquartile ranges) of 7–8 animals per group. **Pb0.01 compared to the respective
vehicle-treated group, Mann Whitney test.
Fig. 5. Effects of 2-DMPI (300 or 1000 μmol/kg, s.c., 2 h before testing; panels A or B,
respectively), moclobemide (300 or 1000 μmol/kg, s.c., 1 h before test; panels C or D,
respectively) or vehicle (10 mL/kg, s.c., 1 or 2 h before test) treatment on the fall
number in the rota-rod test in mice. Values are medians (interquartile ranges) of 7–9
animals per group. **Pb0.01 compared to the respective vehicle-treated group, Mann
Whitney test.
Fig. 6. Effects of 2-DMPI (300 μmol/kg, s.c.), diazepam (1 mg/kg, s.c.) or vehicle
(10 mL/kg, s.c.) administration on anxiety-related behavior in the plus-maze test in
mice. (A) Percentage of time spent in open arms. (B) Percentage of open arm entries.
Values are means±SEM for each group (n=9 per group). *Pb0.05 and **Pb0.01 as
compared with vehicle- and 2-DMPI-treated groups, one-way ANOVA followed by
Student–Newman–Keuls' test.
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decreased in the cerebral cortex (Fig. 7B) and striatum (Fig. 7C).
However, 5-HIAA levels were not signiﬁcantly altered in hippocam-
pus (Fig. 7A). Furthermore, the 5-HIAA/5-HT ratio diminished in all of
the brain regions examined (Fig. 8). We also detected an increase in
DA level and a decrease in DOPAC level in the striatum of 2-DMPI
treated mice (Fig. 7C). The ratios of DOPAC/DA and HVA/DA were
signiﬁcantly reduced only in the striatum (Fig. 8C) Moreover, there
were no alterations in NE or DHPG levels (Fig. 7) or in the DHPG/NE
ratio in any of the brain regions examined (Fig. 8).
3.6. Involvement of the serotonergic and dopaminergic systems in the
antidepressant-like effect of 2-DMPI
Fig. 9A shows that the pretreatment of mice with the nonselective
5-HT receptor antagonist methysergide (2 mg/kg, s.c.) signiﬁcantly
prevented the decrease in the immobility time elicited by 2-DMPI
(300 μmol/kg, s.c.). There was a signiﬁcant effect of treatment x
pretreatment interaction [F(1,36)=7.46, Pb0.01]. Moreover, the
pretreatment of mice with the selective 5-HT1A receptor antagonist
WAY100635 (0.1 mg/kg, s.c.) also prevented the antidepressant-like
effect produced by 2-DMPI (F(1,30)=9.60, Pb0.01 for treatment x
pretreatment interaction; Fig. 9B). In addition, the results depicted in
Fig. 9C show that the pretreatment of animals with the nonselective
DA receptor antagonist haloperidol (0.05 mg/kg, i.p.) prevented the
effect of 2-DMPI in the TST (F(1,32)=9.56, Pb0.01 for treatment×pre-
treatment interaction).
4. Discussion
In the present study, 2-DMPI showed inhibitory activity for both
brain MAO isoforms in mice, with a 30-fold higher selectivity being
Fig. 7.Monoamines and their metabolite levels in the hippocampus (panel A), cerebral
cortex (panel B) and striatum (panel C) of mice treated with vehicle or 2-DMPI
(300 μmol/kg, s.c.). The results are expressed as a percentage of variation versus
respective controls. Each point represents the mean value±SEM of 7–8 animals per
group. Control levels (nanograms per gram of tissue): hippocampus: 5-HT, 1589±51;
5-HIAA, 819±38; DA, 18±2; DOPAC, 123±2; HVA, 137±4; NE, 591±34; DHPG,
104±13; cerebral cortex: 5-HT, 1438±49; 5-HIAA, 488±26; DA, 126±18; DOPAC,
169±9;HVA, 191±8;NE, 470±28; DHPG, 171±14; striatum: 5-HT, 2088±89; 5-HIAA,
939±63; DA, 11280±1041; DOPAC, 2113±168; HVA, 1104±77; NE, 414±37; DHPG,
174±30; *Pb0.05 and **Pb0.01 compared to the respective vehicle-treated group,
unpaired t-test.
Fig. 8. Metabolite/monoamine ratios in the hippocampus (panel A), cerebral cortex
(panel B) and striatum (panel C) of mice treated with vehicle or 2-DMPI (300 μmol/kg,
s.c.). Results are expressed as a percentage of variation versus respective controls. Each
point represents the mean value±SEM of 7–8 animals per group. Control levels
(nanograms per gram of tissue): hippocampus: 5-HIAA/5-HT, 0.52±0.03; DOPAC/DA,
7.37±0.62; HVA/DA, 8.22±0.74; DHPG/NE, 0.17±0.02; cerebral cortex: 5-HIAA/5-
HT, 0.34±0.02; DOPAC/DA, 1.47±0.16; HVA/DA, 1.71±0.24; DHPG/NE, 0.37±0.02;
striatum: 5-HIAA/5-HT, 0.46±0.04; DOPAC/DA, 0.20±0.03; HVA/DA, 0.10±0.01;
DHPG/NE, 0.44±0.09; *Pb0.05 and **Pb0.01 compared to the respective vehicle-
treated group, unpaired t-test.
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agreement with a previous study where 2-DMPI exhibited a higher
selectivity toward cerebral MAO-A than MAO-B in rats (Sant'Anna et
al. 2009). Because 2-DMPI was preferential inhibitor for MAO-A,
kinetic experiments were carried out to further explore the inhibitory
effect of 2-DMPI on MAO-A activity. We found that 2-DMPI caused a
signiﬁcant increase in the Km value and decrease in the Vmax value,
exhibiting a typical proﬁle of a mixed inhibitor. In accordance with
this result, moclobemide behaved as a mixed competitive/noncom-
petitive MAO-A inhibitor when preincubated in vitro with brain
homogenates before exposure to substrate (Da Prada et al., 1989). It
was also observed that MAO-A activity was completely recovered
after 24 h of dialysis. Thus, 2-DMPI was shown to be a mixed,
reversible and preferential MAO-A inhibitor.
Several models of antidepressant-like action have been developed
and used for rapid screening of novel drugs, such as the forced swim
test (FST) and the TST. Similar to the FST, the TST is based on the
observation that mice, after initial escape-oriented movements,
develop an immobile posture when placed in an inescapable stressfulsituation. The TST has been argued to be less stressful than the FST
and has greater pharmacological sensitivity (Cryan et al., 2005). In
this study, 2-DMPI decreased the immobility time when administered
subcutaneously 2 h before TST at 100, 300 and 1000 μmol/kg,
exhibiting an antidepressant-like effect. Moclobemide also exhibited
an antidepressant-like action, decreasing the immobility time at 100
and 300 μmol/kg. However, this agent signiﬁcantly increased the
immobility time at a dose of 1000 μmol/kg, due to a dysfunction in
motor activity as observed in the rota-rod test. This result is in
agreement with a previous study showing that moclobemide causes
impairment in motor performance at higher doses (Burkard et al.,
1989). The efﬁcacy of 2-DMPI and moclobemide for reducing
immobility time was similar (Imax values of 46±6 or 40±7% for the
dose of 300 μmol/kg, respectively). In accordance with our results,
other reversible MAOIs, including beﬂoxatone and toloxatone, have
been demonstrated to be effective in reducing the immobility time in
the TST (Prakhie and Oxenkrug, 1998; Steru et al., 1987).
Mice submitted to the TST are usually also tested in the open ﬁeld
test to dissociate locomotor stimulant action from the antidepressant-
like effect of antidepressants (Steru et al., 1985). 2-DMPI, at a dose that
Fig. 9. Effect of pretreatment of mice with methysergide (2 mg/kg, s.c.; panel A),
WAY10635 (0.1 mg/kg, s.c.; panel B) or haloperidol (0.05 mg/kg, i.p.; panel C) on the
anti-immobility effect of 2-DMPI (300 μmol/kg, s.c.) in the TST. Values are means±
SEM for each group (n=7–10 per group). ***Pb0.001 compared with the respective
vehicle-treated group, two-way ANOVA followed by Bonferroni's test.
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locomotor activity compared with vehicle-treated mice. The effect of
2-DMPI (300 and 1000 μmol/kg, s.c.) was also evaluated in the rota-
rod test, and no changes in motor coordination activity were
observed. These results suggest that the antidepressant-like activity
of 2-DMPI in the TST was not mediated by an unspeciﬁc stimulation
of locomotor activity and that this compound did not cause any
dysfunction in motor performance, even at high doses.
As some antidepressants may also possess anxiolytic properties
(Liu et al., 2010), we investigated the effect of 2-DMPI on the mouse
plus-maze test. Results showed that 2-DMPI did not alter the
percentage of time or the percentage of entries into the open arms
compared to the control, suggesting that 2-DMPI did not present
anxiolytic properties. This result is in agreement with previous
studies showing that acute treatment with others MAOIs, including
moclobemide, phenelzine and beﬂoxatone, had no anxiolytic effects
in several animal anxiety models (Graeff et al., 1998; Griebel et al.,
1997, 1998; Hascoët et al., 2000; Holmes and Rodgers, 2003).
Monoamine neurotransmitters, such as 5-HT, NE and DA, are
believed to be involved in depressive disorders and play important
roles inmediating behavioral effects of antidepressant drugs (Elhwuegi,
2004; Millan, 2004). In order to investigate if the antidepressant-likeeffect of 2-DMPIwas due toMAO-A inhibition, wemeasured the ex vivo
levels of monoamines and their metabolites in three brain structures
(cerebral cortex, hippocampus and striatum). It has been proposed that
these brain regions might mediate certain symptoms of depression,
such as cognitive abnormalities and anhedonia (Berton and Nestler,
2006). 2-DMPI, at a dose (300 μmol/kg, s.c.) and time (2 h before
testing) sufﬁciently effective to exert an antidepressant-like effect,
signiﬁcantly increased 5-HT levels in the cerebral cortex and hippo-
campus of mouse brain. Additionally, a decrease in 5-HIAA levels was
detected in the striatum and cerebral cortex. Also, therewas an increase
in DA levels and a decrease in DOPAC levels in the striatum of 2-DMPI-
treated mice. However, NE and DHPG levels were not altered in any
brain region. Thus, the antidepressant-like effect of 2-DMPI in the
TST appears to be mediated by 5-HT and DA neurotransmitters but not
by NE.
The ratio of the major metabolite to the corresponding monoamine
is commonly used as an index of monoamine turnover (Kitanaka et al.,
2005, 2006; Miura et al., 1996). In this study, 2-DMPI induced a
decrease in 5-HIAA/5-HT ratios in all of the brain regions examined,
indicating a reduction in 5-HT turnover. DA metabolism also was
diminished but only in the striatum, as indicated by the diminution in
both DOPAC/DA and HVA/DA ratios. Conversely, NE turnover was not
affected in the three brain areas analyzed. These results strongly
indicate that 2-DMPI exerts it antidepressant-like action by decreasing
5-HT and DA turnover, and consequently, elevating the availability of
these neurotransmitters in speciﬁc regions of the brain.
As only 5-HT and DA metabolism were changed by 2-DMPI
treatment, we further investigated the involvement of both serotoner-
gic and dopaminergic systems in its antidepressant-like effect in the
TST. The effects of certain pharmacological antagonists of serotonergic
and dopaminergic receptors were evaluated for the anti-immobility
action of 2-DMPI (300 μmol/kg, s.c., 2 h before testing) in mice.
Methysergide, a non-selective 5-HT receptor antagonist, is a
useful tool used to investigate the participation of the serotonergic
system in behavioral responses (Duarte et al., 2008; Rodrigues et al.,
2005; Zomkowski et al., 2004). In this study, the anti-immobility
effect of 2-DMPI was abolished when mice were pretreated with
methysergide, thereby conﬁrming the involvement of the seroto-
nergic system in the antidepressant-like effect, as observed in
monoamine measurement. Several studies have suggested that
5-HT1A receptors are particularly relevant to the antidepressant
responses of numerous antidepressant drugs (Blier and Ward, 2003;
Elhwuegi, 2004). Some 5-HT1A partial agonists (such as gespirone
and buspirone) have been reported to exert an antidepressant
activity in numerous clinical trials (Feiger, 1996; Feiger et al., 2003;
Jenkins et al., 1990; McGrath et al., 1994; Robinson et al., 1990). In
addition, Haddjeri et al. (1998) demonstrated that various antide-
pressant treatments, including MAO-A inhibition, might alleviate
depression by enhancing the tonic activation of forebrain postsyn-
aptic 5-HT1A receptors. In our study, the pretreatment of mice with
the selective 5-HT1A receptor antagonist WAY100635 was able to
prevent the anti-immobility effect produced by 2-DMPI, suggesting
that this receptor subtype is involved in the mechanism for the
antidepressant-like action of 2-DMPI in the TST.
Dopamine is believed to play a critical role in the neurobiology of
depression and in the mechanism of action of certain antidepressant
drugs (Dailly et al., 2004; Dunlop and Nemeroff, 2007; Papakostas,
2006). In addition, a dysfunction of mesolimbic and mesocortical
dopaminergic pathways is primarily implicated in the melancholic and
cognitive features in depression, respectively (Millan, 2004). A number
of reports have suggested that depression may be linked to abnormally
low DA levels and that the severity of the disorder is inversely
correlated with central nervous system DA metabolite levels (Hamner
and Diamond, 1996; Roy et al., 1985). In this study, the anti-immobility
effect of 2-DMPI was prevented by the pretreatment of mice with
the nonselective dopaminergic antagonist haloperidol, conﬁrming the
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activity in the TST. In agreement with this result, others have shown
that dopaminergic agents present antidepressant-like activity in
preclinical experiments. Dhir and Kulkarni (2007) showed that the
D2/D3 agonist ropinirole presented antidepressant-like activity in both
the TST and the FST. Furthermore, quinpirole (a D2-like receptor
agonist) produced a signiﬁcant decrease in immobility time in the
rat FST, which was blocked by haloperidol (Basso et al., 2005).
As evidence showing that antidepressants with actions on
multiple neurotransmitters have therapeutic advantages over selec-
tive serotonin reuptake inhibitors (SSRIs) increases, new antidepres-
sant agents are likely to have this property (Nash and Nutt, 2007).
Based on the pivotal role proposed for DA in depression, it has been
hypothesized that a broad-spectrum antidepressant will produce a
more rapid onset and/or higher efﬁcacy than agents inhibiting the
reuptake of 5-HT and/or NE (Skolnick et al., 2003). Furthermore, it is
quite possible that the treatment of major depressive disorders with
agents having pro-dopaminergic activity, such as MAOIs, may result
in the greater resolution of certain symptoms of depression, such as
fatigue, lethargy and hypersomnia, versus treatments with predom-
inantly serotonergic or noradrenergic activity, such as the SSRIs and
tricyclic antidepressants (Papakostas, 2006). Therefore, 2-DMPI could
be a promising compound, as it inhibited brain MAO-A activity and
presented antidepressant-like activity by a mechanism dependent
of both serotonergic and dopaminergic systems.
5. Conclusion
Taken together, our results demonstrate that 2-DMPI is a new,
reversible and preferential MAO-A inhibitor that exerts its antide-
pressant-like activity by decreasing 5-HT and DA turnover without
disrupting motor performance, even at high doses. Therefore, this
compound may be a prototype for the development of novel agents
with potential therapeutic value for the management of depression.
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